Daré Bioscience, Inc. (NASDAQ:DARE) Short Interest Down 79.8% in June

Daré Bioscience, Inc. (NASDAQ:DARE) saw a large decline in short interest in the month of June. As of June 30th, there was short interest totalling 35,000 shares, a decline of 79.8% from the June 15th total of 172,900 shares. Approximately 0.4% of the shares of the company are sold short. Based on an average daily volume of 67,200 shares, the short-interest ratio is currently 0.5 days.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. Brookline Capital Management raised Daré Bioscience from a “hold” rating to a “buy” rating and set a $36.00 price target for the company in a report on Wednesday, May 15th. HC Wainwright reissued a “buy” rating and issued a $72.00 target price on shares of Daré Bioscience in a report on Wednesday, May 15th.

Daré Bioscience Stock Up 3.6 %

DARE stock traded up $0.12 during trading on Friday, reaching $3.48. 23,491 shares of the company were exchanged, compared to its average volume of 49,825. Daré Bioscience has a 52-week low of $3.05 and a 52-week high of $10.95. The stock’s 50 day moving average price is $4.65 and its 200 day moving average price is $4.74.

Daré Bioscience (NASDAQ:DARE) last released its quarterly earnings results on Tuesday, May 14th. The biotechnology company reported ($0.84) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.12). The company had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.52 million. During the same quarter in the prior year, the company posted ($1.08) EPS. On average, research analysts expect that Daré Bioscience will post -2.57 earnings per share for the current fiscal year.

About Daré Bioscience

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.